We partner with a secure submission system to handle manuscript submissions.
Please note:
You will need an account for the submission system, which is separate to your Cambridge Core account. For login and submission support, please visit the
submission and support pages.
Please review this journal's author instructions, particularly the
preparing your materials
page, before submitting your manuscript.
Click Proceed to submission system to continue to our partner's website.
To save this undefined to your undefined account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your undefined account.
Find out more about saving content to .
To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Objectives/Goals: Identify genetic variants associated with the development of diabetic retinopathy (DR) and its advanced complication, diabetic macular edema (DME). Despite DME being a leading cause of vision loss among people with diabetes, genetic findings have been limited by small sample size, underrepresentation of diverse populations, and poor study design. Methods/Study Population: Genome-wide association studies (GWAS) were conducted to identify genetic variants linked to DME. GWAS were conducted separately by ancestry (African, European, and Admixed American) in the Million Veteran Program and All of Us cohorts, adjusted for age, sex, BMI, diabetes duration, mean HbA1c, and 10 principal components. We then combined population groups to perform a multi-ancestry meta-analysis (Multi) using a software called METAL. Analyses included autosomes and chromosome X for DME versus DR controls (14,211 cases and 47,005 controls). Gene expression analyses were performed using S-PrediXcan across 49 tissues to identify genes whose predicted expression is associated with DME risk. APOL1 variant and haplotype analyses were conducted to assess ancestry-specific associations with DME and type 2 diabetes. Results/Anticipated Results: Genome-wide significant loci included G6PD (Multi and African), previously reported to influence diabetes diagnosis, and APOL1 (Multi and European), previously linked to kidney disease in African ancestry. Gene expression analyses revealed 32 significant gene–tissue pairs (Multi 18 and African 18), corresponding to 9 unique genes. In APOL1, E150K was strongly associated with DME in Europeans (OR=1.22, P=2.9×10−8) and modestly in Africans (OR=1.18, P=5.3×10−4). N264K also showed significant effects in Europeans (OR=1.42, P=9.8×10−4) and weaker but consistent effects in Africans (OR=1.04, P=0.025). The high-risk G1/G2 haplotype demonstrated a modest association in African ancestry (OR=1.15, P=0.048). Discussion/Significance of Impact: This is the largest genetic study of DME, uncovering genetic risk factors that could potentially be driving risk, such as APOL1, a gene historically tied to kidney disease among individuals of African ancestry. Our results indicate its involvement may extend to diabetic complications more generally.
Objectives/Goals: The objective of this study was to identify subgroups of young adults with type 1 diabetes (T1D) defined by HbA1c measured 12 months after participating in a randomized controlled trial for a behavioral intervention. Methods/Study Population: This study is a secondary, exploratory analysis of 76 young adults with T1D with complete data who enrolled in the DiaBetter Together RCT. A regression tree model is used to identify subgroups of participants according to HbA1c measured 12-month post-enrollment. Predictors include baseline participant characteristics, questionnaire scores, and clinical characteristics. Model fit is informed by restricted sum of squares, pruned using cost complexity assessment, and number of observations per node. Results/Anticipated Results: The final regression tree predicting 12m HbA1c included two branches and five leaves defined by baseline HbA1c, Diabetes Distress: Friend/Family (DDFF), and Diabetes Strengths: Getting help with diabetes management (DSGMH). Participants with baseline HbA1c <6.87% had the lowest mean 12m HbA1c (M=6.5, SD=0.7). Two unique subgroups were identified among patients with baseline HbA1c between 6.87 and 9.91 defined by DSGMH. The mean 12m HbA1c was 8.13 (SD=1.1) and 10.0 (SD=2.6) for DSGMH ≥6.06 and <6.06, respectively. Among patients with baseline HbA1c>9.91, two unique subgroups were defined by DDFF. The mean 12m HbA1c was 9.99 (SD=1.5) if DDFF <3.55. The highest 12m HbA1c was observed among participants with baseline HbA1c ≥9.91% and DDFF≥3.55 (M=13.0, SD=0.7). Discussion/Significance of Impact: Baseline HbA1c, DDFF, and DSGMH were important predictors of subgroups of patients defined by 12m HbA1c. Psychosocial variables were important predictors beyond demographic and clinical variables. Clinicians and researchers may wish to target interpersonal aspects of diabetes distress and strengths in work with young adults with T1D.
Objectives/Goals: To examine gut microbiome–immune interactions that may contribute to respiratory dysfunction in Puerto Rican patients with primary ciliary dyskinesia (PCD), aiming to identify novel biomarkers that inform targeted interventions and address health disparities in rare diseases. Methods/Study Population: This cross-disciplinary pilot study integrates clinical, genomic, and microbiome data from patients with PCD carrying the Puerto Rican RSPH4A founder variant (c.921+3_6delAAGT; n = 8) and healthy controls (n = 8). Fecal samples will undergo 16S rRNA V4 sequencing and bioinformatic profiling using QIIME2, ANCOM, and PICRUSt2. Plasma cytokines (IL-6, IL-8, TNF-α, and IL-10), CRP, and ESR quantify systemic inflammation, while pulmonary tests (FEV₁ and FVC) will assess lung function. Correlation analyses will define microbial taxa linked to inflammatory and respiratory outcomes, elucidating the role of the gut–lung axis in disease progression. Results/Anticipated Results: We anticipate reduced microbial diversity and enrichment of pro-inflammatory taxa (e.g., Bacteroides and Prevotella) in PCD participants. Microbial shifts are expected to correlate with elevated inflammatory cytokines and decreased lung performance. These findings will highlight gut dysbiosis as a modifiable driver of inflammation, offering a foundation for future translational interventions such as diet or probiotic therapies. Discussion/Significance of Impact: This study advances precision medicine for rare lung diseases by elucidating gut–lung axis mechanisms in a genetically defined Puerto Rican PCD cohort, generating foundational data for future microbiome-targeted therapies and strengthening Puerto Rico’s translational research capacity.
Objectives/Goals: Biological heterogeneity within psychosis spectrum disorders has proven to be a major obstacle in identifying reproducible pathophysiologic markers of disease. Here, we used normative modeling to assess cortical thickness deviations at the individual level. We then grouped patients into subgroups based on number of deviations. Methods/Study Population: T1 MPRAGE scans from 113 antipsychotic-naive first-episode psychosis patients were normatively modeled as well as 397 unrelated individuals from HCP Young Adult. The patients were subdivided by whether they had a greater than expected number of large deviations in cortical thickness across all regions by comparing norms established in the HCP dataset. Results/Anticipated Results: We identified four distinct subgroups of patients who more commonly share spatial deviation patterns compared to the overall group. The positive deviation subgroup, negative deviations subgroup, and both positive and negative deviations subgroups were larger in the first-episode psychosis sample than would be predicted from the healthy control data. Discussion/Significance of Impact: Our data provide further evidence for the existence of subtypes of psychosis spectrum disorder that differ in patterns of cortical thickness, specifically a subtype with increased cortical thickness. Normative modeling approaches might constitute an important step toward precision psychiatry.
Objectives/Goals: Treatments for adults with anorexia nervosa (AN) are inadequate, with no FDA-approved medications and only 30% achieving remission in psychotherapy trials. This ongoing KL2-funded pilot study evaluates Exposure Therapy for AN (Exp-AN), which targets anxiety about weight gain – a key mechanism maintaining AN. Methods/Study Population: Preliminary results (target N=16) include six adults (100% female, 83% White, 17% Black, ages 18–24, mean=20.5 years) with AN or atypical AN who have completed Exp-AN, a standardized 20-session outpatient therapy delivered in both in-person and virtual formats over 20 weeks. Exp-AN combines in vivo (e.g., stepping on a scale) and imaginal (e.g., listening to scripts about catastrophic weight gain) exposures to challenge anxious beliefs and enhance tolerance related to weight gain. Measures assessing treatment acceptability, AN symptomatology, and anxiety about weight gain were administered at baseline and end-of-treatment. Mean scores and effect sizes were calculated and compared to predetermined benchmarks to evaluate preliminary signals of acceptability, efficacy, and target engagement. Results/Anticipated Results: On two acceptability items (scale: 1=“not at all” to 7=“extremely”), participants rated Exp-AN as 5.8/7 on helpfulness and 6.3/7 on logic, meeting our 5/7 benchmark. All within-subjects effect sizes (Cohen’s d from paired samples t-tests) met our benchmark for large effects (d≥0.8), indicating improvements from baseline to end-of-treatment in: AN symptomatology (d=1.37), anxiety ratings about weight gain (d=1.22), anxious beliefs about weight gain (d =1.06), and tolerance of weight gain (d=1.40). Pearson’s correlations exploring whether changes in weight gain anxiety were associated with AN symptom improvement met our benchmark (r≥0.5) for anxiety ratings (r=0.55) and anxious beliefs (r=0.65), but not tolerance of weight gain (r=0.18). Discussion/Significance of Impact: Results support Exp-AN’s acceptability and preliminary efficacy. Reductions in weight gain anxiety correlated with symptom improvement, suggesting target engagement. By targeting specific mechanisms, this work advances precision medicine and treatment optimization. Findings warrant a fully powered randomized controlled trial.
Objectives/Goals: Hepatocellular carcinoma (HCC) is a therapeutic challenge due to poor tumor immunogenicity, low endogenous T cell response, and a complex tumor microenvironment (TME). We propose an immunotherapeutic strategy leveraging widespread antiviral immunity – particularly memory T cells against SARS-CoV-2 spike (SPIKE) – to redirect T cells into tumors. Methods/Study Population: By engineering oncolytic viruses (OV) to express SPIKE, the approach aims to recruit virus-specific T cells and re-activate them through viral boosting, enhancing tumor clearance. This has been successfully shown in a B-16 melanoma model, another solid tumor system. We will also develop a dual-specific CAR T cell platform against SPIKE and GPC3, the most common HCC tumor-associated antigen (TAA), enabling antitumor targeting which can also benefit from OV readministration. The experimental plan includes purification and titration of a single-cycle adenovirus expressing SPIKE (SC-Ad-SPIKE), infection of murine and human HCC cell lines to validate SPIKE expression and replication, and in vivo treatment of subcutaneous or orthotopic murine tumors in pre-immunized or naïve mice using OV. Results/Anticipated Results: This strategy offers a translatable platform to re-focus existing antiviral memory toward otherwise weakly immunogenic tumors like HCC, potentially enhancing clinical efficacy through oncolytic virotherapy and CAR T cell engineering. We should see better average tumor clearance and survival in the groups treated with the OV and CAR T against SPIKE than controls with only GPC3 given the lack of reliance on tumor-GPC3 expression. Discussion/Significance of Impact: Our approach could be crucial for patients given how varied current responses are to available therapies. The combination of a generalized OV therapy and a more targeted CAR T provides a promising new solution to the current unmet need of many HCC patients globally.
Objectives/Goals: To develop and assess a multidimensional measure of arousability by integrating respiratory, autonomic, cortical, and movement-related events and to identify sex-specific arousal phenotypes using clustering analyses and LASSO-based machine learning for feature selection and model optimization. Methods/Study Population: We will conduct a retrospective cross-sectional analysis using sleep and clinical data from >10,000 adults in three different cohorts. Arousability will be defined by event-level metrics across respiratory, autonomic, cortical, and movement domains. Variable clustering will be used to construct a multidimensional composite index of arousability based on those domains. Generalized linear models will test sex differences in individual metrics composite indices. LASSO regression will be applied to select arousability features most predictive of sex, mortality, and cardiovascular disease (CVD). Results/Anticipated Results: We anticipate identifying distinct arousability dimensions and sex-specific arousal profiles. Women are expected to show greater non-respiratory arousals, while men will show higher respiratory-related arousals. The resulting multidimensional index will capture arousal burden more comprehensively than traditional metrics like the apnea–hypopnea index. This will aid in understanding sex-based difference of sleep fragmentation, as well as understanding the sleep mechanisms most associated with mortality and CVD. Discussion/Significance of Impact: This study will advance precision sleep medicine by developing a multidimensional, data-driven arousability index and identifying sex-specific phenotypes. These findings may improve diagnostic accuracy, influence tailored interventions, and inform risk stratification beyond traditional metrics.
Objectives/Goals: Limited systematic analysis of real-world evidence (RWE) on pharmacogenomic (PGx) testing utility, which can help provider decision-making and avoid serious adverse effects, exists. This study explores clinical-behavioral outcomes and implementation considerations, for PGx testing in real-world clinical settings for PGx biomarker CYP2D6. Methods/Study Population: Our systematic review investigated drug–gene pairs with strong evidence (Level A, Final classification by the Clinical Pharmacogenomics Implementation Consortium [CPIC]) for CYP2D6. Search strings were deployed across Google Scholar, PubMed, Scopus, and Semantic Scholar. Papers were included only if they presented, measured, and/or described real-world clinical or patient and/or provider behavioral outcomes based on EHR or claims data assessment following PGx testing for the CYP2D6 biomarker, included PGx biomarker(s)–drug pairs with CPIC Level A, Final Evidence designations, and published in English. Study quality and bias risks were assessed using the Newcastle–Ottawa scale or A comprehenSive tool to Support rEporting and critical appraiSal…of reSearch outcomes (ASSESS) tools, where applicable. Results/Anticipated Results: Of the 218 articles identified, 25 met our inclusion criteria and explored 9 CPIC Level A, Final CYP2D6–drug pairs. Overarching qualitative themes were 1) variation in CYP2D6 biomarker testing and interpretation and 2) PGx test implementation and data considerations. CYP2D6–drug pairs were reported across four therapeutic areas (analgesia [n = 21], psychiatry [n = 17], oncology [n = 7], and gastroenterology [n = 6]) with the two most researched drugs being codeine (n = 21) and tramadol (n = 18). Six (6) articles reported PGx clinical outcomes, considered to be a “measurable change in symptoms, overall health, ability to function, quality of life, or survival outcomes” in relation to PGx testing. Discussion/Significance of Impact: Our findings indicate a need to address both inconsistent phenotype categorization and racial, ethnic, and genetic ancestry classifications and to improve EHR interoperability with PGx test results. Future RWE-PGx studies should associate dosage and regimen changes to both discrete provider choices and patient clinical-behavioral outcomes.
Objectives/Goals: Dietary variation can compromise metabolic control in phenylketonuria (PKU), yet the impact of improved management on within-subject dietary variation has not been explored. We examined the effect of a 5-day nutrition education camp on dietary variation and metabolic control in females with PKU. Methods/Study Population: Females with PKU (n=103; ages 12–59 years, median=18) who attended the Emory Metabolic Camp from 2014 to 2025 were included in the analysis. Pre- and post-camp 3-day diet records (3DDR) and blood samples (camp day 1 and day 5) were collected. Within-subject coefficients of variation (CVw) in energy, total protein, medical food protein, intact protein, and Phe were calculated from pre- and post-camp 3DDR. Wilcoxon signed-rank tests were used to assess pre- and post-camp dietary variation, and linear mixed models adjusted for age and energy intake were used to examine the relationship between changes in dietary variation and blood Phe concentrations. Results/Anticipated Results: Median (IQR) pre- to post-camp energy intake increased from 1475 (1207–1832) to 1733 (1459–2054) kcal, medical food protein intake increased from 36 (13–54) to 40 (18–54) g, intact protein intake decreased from 17 (10–29) to 12 (7–26) g, and Phe intake decreased from 641 (409–1152) to 527 (332–1015) mg. Blood Phe decreased from 529 (290–895) to 385 (196–721) μmol/L. CVw significantly decreased from pre- to post-camp for energy (p<0.001), intact protein (p<0.05), and Phe (p <0.05), and a reduction in energy CVw was associated with lower blood Phe (p <0.05). Notably, greater dietary variation in energy, total protein, and intact protein intake was associated with higher blood Phe at pre-camp but not at post-camp, suggesting improved metabolic stability after intervention. Discussion/Significance of Impact: These findings demonstrate that a 5-day nutrition education intervention in a large PKU cohort optimized dietary stability and resulted in improved metabolic control, providing strong evidence to support recent FDA guidance on optimizing and standardizing diet prior to and throughout inherited metabolic disorder clinical trials.
Objectives/Goals: This collaboration explores magnetic-responsive scaffolds toward modeling Salmonella infection via the small extracellular vesicle (sEV) route. We aim to elucidate the mechanism by which sEVs reflect host–pathogen interactions to inform new Salmonella therapeutics. Methods/Study Population: Human intestinal epithelial cells (INT-407) are being cultured on magnetic-responsive scaffolds under controlled mechanical stimulation and infected with Salmonella Typhimurium 12023 WT. Kinetic assays are assessed via confocal microscopy, flow cytometry, and qPCR. sEV isolation is being performed by NanoPoms immunomagnetic capture and characterized by nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM), and Western blotting for canonical markers (CD9, CD63, and CD81). Additionally, sEVs derived from human THP-1 cells are being used to treat naïve INT-407, in which cytokine responses and proteomic shifts are analyzed. Results/Anticipated Results: We anticipate that INT-407 in 3D magnetic scaffolds will shift the Salmonella infection kinetics compared to the unstimulated controls and traditional 2D culture. We expect the sEVs from infected cells to be enriched in antigenic proteins and canonical sEV markers. Furthermore, sEVs from infected THP-1 cells are anticipated to induce pro-inflammatory cytokine release and proteomic shifts toward intracellular signaling and inflammatory processing in naïve INT-407 following treatment. Taken together, these findings will elucidate the mechanism by which magnetic-responsive scaffolds better recapitulate the gut microenvironment for modeling host–pathogen interactions. Discussion/Significance of Impact: This project’s findings will indicate if 3D magentic scaffolds provide a sound model for Salmonella infection. Analysis of sEVs derived from INT-407 and THP-1 will provide insight into the functional characteristics sEVs have in the gastrointestinal environment upon pathogen insult.
Objectives/Goals: We sought to describe perspectives among Black nursing professionals and community leaders regarding the return of genetic test results and place perspectives into context with aggregated findings in the All of Us Research Program’s Data Browser. Methods/Study Population: Semi-structured, virtual interviews were held with adults (≥18 years of age) self-identifying as Black. A two-step thematic analysis process was used to assess interviewee perspectives with (sub)themes identified in the literature across two topics: drug/medication response and hereditary disease risk. Themes were placed into context with Data Browser content, focusing on genes and their respective alleles with frequencies ≥0.10 in African ancestry populations in All of Us. Results/Anticipated Results: Interviewee perspectives aligned with two known themes (research engagement and care), with five emerging subthemes. In the Data Browser, seven alleles were observed with frequencies ≥0.10 for three pharmacogenomic (PGx) biomarkers for African ancestry populations:CYP2C19 (SNV, 10-94761900-C-T; SNV,10-94775367-A-G; SNV 10-94781859-G-A), DPYD (SNV, 1-97883329-A-G; SNV, 1-97515839-T-C), and UGT1A1 (insertion, 2-233760233-C-CAT; SNV, 2-233757136-G-A). Also, four alleles were observed with frequencies ≥0.10 for three genes implicated in hereditary disease risk, two of which hold PGx implications: CACNA1S (PGx, SNV, 1-201112815-C-T; SNV, 1-201110107-C-T), SCN5A (no PGx, SNV, 3-38603929-T-C), and TP53 (PGx, SNV, 17-7676154-G-C). Discussion/Significance of Impact: Our findings convey important clinical and translational science considerations for individuals and community leaders of African ancestry and researchers seeking reputable, publicly available information to understand, communicate, and act on genomic findings.
Objectives/Goals: Sporadic Alzheimer’s disease (sAD) lacks effective preventive therapies, underscoring the need to target upstream pathogenic drivers. We identified an evolutionarily expanded role for postsynaptic mGluR3 receptors in DLPFC and ERC regions, where they regulate cAMP–calcium-K+ channel signaling to sustain neuronal firing and working memory. Methods/Study Population: Here, we employed liquid chromatography–tandem mass spectrometry (LC-MS/MS) to define the proteomic consequences of chronic 2-MPPA treatment in vulnerable (ERC and DLPFC) versus resilient (primary visual cortex) regions. Aberrant calcium signaling, closely linked to neuroinflammation, is an early event in sAD. Aged rhesus macaques, naturally APOE-ε4 homozygotes, show cognitive decline, calcium dysregulation, amyloid deposition, and tau pathology, providing a translational model. mGluR3 signaling is driven by N-acetylaspartylglutamate (NAAG) and constrained by glutamate carboxypeptidase II (GCPII), whose expression rises with age/inflammation and is inhibited by 2-MPPA, providing an opportunity to interrogate unique therapeutic strategies in vulnerable primate cortices. Results/Anticipated Results: We identified >2,400 proteins across experimental conditions, and label-free quantification revealed region-specific differential expression patterns paralleling known vulnerability gradients in sAD. Gene ontology enrichment implicated pathways governing protein deneddylation, amyloid and tau-associated processes, synaptic plasticity, mitochondrial homeostasis, electron transport chain, and oxidative stress, revealing putative targets for therapeutic intervention in sAD. Chronic inhibition of GCPII with oral bioavailable inhibitor 2-MPPA improved task-related neuronal firing critical for higher-order cognition, working memory behavioral performance, and reduced pT217Tau pathology, the most robust biomarker that heralds future neurodegeneration in aged macaques and sAD. Discussion/Significance of Impact: GCPII inhibition activates region-specific molecular programs in the aging primate cortex, protecting circuits vulnerable to sAD. The proteomic signatures reveal candidate biomarkers and targets for preventing calcium-driven degeneration, warranting deeper study of these therapeutic pathways in dementia and neurodegenerative disorders.
Objectives/Goals: This study evaluates the correlation between coronary artery calcium (CAC) scores and arteriosclerotic disease progression, determining if CAC scoring can predict high-risk individuals and guide early interventions to improve cardiovascular outcomes and disease prevention. Methods/Study Population: The retrospective descriptive study analyzed 800 coronary calcium scoring (CCS) reports to evaluate patterns of CAC scores and their relationship to arteriosclerotic disease progression. Data were collected from the Hospital Cardiovascular de Puerto Rico, focusing on CCS reports generated in 2024. The study population included patients aged 21 years and older who underwent CAC scoring during 2024. Instruments included radiology reports containing CAC scores and medical records detailing patient demographics, clinical history, and outcomes. Descriptive and correlation analyses were performed to explore associations between CAC scores and arteriosclerotic disease. Results/Anticipated Results: Preliminary findings from 800 CCS reports revealed that over half of the participants presented measurable coronary calcification, mainly among those aged 45–84 years with hypertension, diabetes, or hyperlipidemia. These results highlight the importance of CAC scoring as a noninvasive, cost-effective tool for early detection of subclinical atherosclerosis, enabling timely intervention and improved cardiovascular risk assessment. The study underscores its value in guiding prevention strategies and reducing disease burden. Discussion/Significance of Impact: This study highlights the calcium score as a precise, noninvasive tool for early detection of cardiovascular disease. It improves risk prediction and guides timely, targeted interventions to prevent complications and support effective, evidence-based cardiovascular prevention strategies.
Objectives/Goals: Endometrial cancer (ECa) incidence is rising rapidly in women under 40 years of age, and response rates and progression-free survival remain poor in advanced ECa. New targeted therapies are urgently needed. The objective of this study is to develop and test a potent inhibitor that targets midkine (MDK) for treating ECa. Methods/Study Population: Using the three-dimensional structure of human MDK, we rationally designed a small organic molecule (HBS-101) that directly binds with MDK and that functions as a MDK inhibitor. Microscale thermophoresis assay (MST) and in silico docking studies were used to demonstrate direct binding of HBS-101 to MDK. In vitro activity was tested using MTT, clonogenicity, and apoptosis assays. Mechanistic studies were conducted using Western blot, RT-qPCR, STAT3 and NFkB reporter gene assays, RNseq, and TEM. Status of MDK in ECa was determined using TNMplot database. Pharmacokinetics, Maximum Tolerable Dose, and in vivo efficacy studies were conducted using mouse models. HBS-101 efficacy in chemotherapy-resistant ECa was demonstrated using therapy-resistant primary ECa (TR-ECa) cells generated in-house. Results/Anticipated Results: MDK is highly expressed in ECa tumors compared to normal tissues. MDK and its receptors are expressed in established and primary ECa cell lines. Knockdown of MDK reduced ECa cell proliferation and colony formation. HBS-101 directly binds to MDK with nanomolar affinity, and a potential interaction surface on MDK was identified. HBS-101 decreased ECa cell viability and colony formation with an IC₅₀ ranging from 0.5 to 5 µM. Mechanistic studies showed that HBS-101 suppressed STAT3 and NFκB activity and induced cell death, ER stress, and ferroptosis. TR-ECa cells exhibited sensitivity to HBS-101. HBS-101 possesses favorable drug-like properties, including oral bioavailability, in vivo stability and little in vivo toxicity up to 10 mg/kg. HBS-101 significantly inhibited tumor growth in ECa PDX models. Discussion/Significance of Impact: HBS-101 is a novel therapeutic agent that targets MDK via a unique mechanism, shows favorable pharmacokinetics, and induces apoptosis and ferroptosis in ECa cells by blocking MDK signaling. HBS-101 shows promise in treating high-grade and therapy-resistant ECa and may help overcome the current lack of good treatment options for these patients.
Objectives/Goals: To develop a comparative framework evaluating FDA regulatory pathways for ADCs in HER2-low and TNBC, mapping biomarker translation, approval timelines, and labeling language, and conducting qualitative and quantitative analyses to identify determinants of global therapeutic access. Methods/Study Population: This study conducted a targeted review of scientific, regulatory, and epidemiological databases to examine the US FDA’s regulatory pathways for ADCs in HER2-low and TNBC populations. Literature from PubMed and Scopus was analyzed to trace the translation of biomarkers from gene targets to therapeutic moieties. FDA databases were reviewed to map approval timelines, labeling language, and evidentiary standards shaping ADC authorization. ClinicalTrials.gov, SEER, and GLOBOCAN data were integrated to contextualize trial geography, disease burden, and access disparities. Comparative synthesis connected molecular biomarker validation to regulatory decision-making, enabling the identification of translational and policy determinants influencing time to patient access within the FDA landscape. Results/Anticipated Results: Preliminary findings indicate that advances in biomarker characterization have accelerated the development and regulatory progression of ADCs in breast cancer. HER2-low and Trop-2 expression have enabled the evolution of Enhertu and Trodelvy from histopathological to molecularly guided indications. FDA approvals demonstrated reduced timelines and more detailed biomarker-specific labeling, supported by surrogate endpoints such as progression-free survival and overall response rate. Analysis of approval data and clinical trial mapping highlights a temporal correlation between biomarker discovery, therapeutic innovation, and expedited regulatory authorization for targeted ADC therapies, serving as a pathway toward improved global access. Discussion/Significance of Impact: This study provides a structured analysis of FDA regulation of ADCs in breast cancer, linking biomarker translation to therapeutic approval. Findings underscore the need for evidence-based and equity-driven frameworks to accelerate global access and support ADC transition to first-line therapy.
Objectives/Goals: To integrate proteomic and metabolomic profiling with genetic literacy and patient experience data to uncover biological mechanisms, community perceptions, and barriers to care in Puerto Ricans affected by Huntington’s disease. Methods/Study Population: We conducted a mixed-methods, multi-omic study combining quantitative proteomic and metabolomic analyses with surveys and interviews exploring genetic literacy and access to care. Participants included patients, first-degree relatives, and controls recruited through PR Huntington Foundation (Fundación Huntington Puerto Rico). Plasma samples were analyzed via mass spectrometry to identify differential protein and metabolite expression associated with CAG repeat length, clinical stage, and symptom burden. Qualitative data captured perceptions of genetics, stigma, and support networks. Results/Anticipated Results: Multi-omic analysis revealed disruptions in energy metabolism, oxidative stress response, and mitochondrial pathways, including altered creatine kinase, apolipoproteins, and kynurenine metabolites. These signatures correlated with CAG repeat length and disease severity. Qualitative findings showed limited genetic literacy, lack of formal counseling, and reliance on community organizations for support. Participants emphasized the need for accessible education and culturally adapted care models. Discussion/Significance of Impact: Integrating omics with community insights highlights both biological and social determinants of disease burden. The findings underscore the significance of equitable precision medicine, culturally grounded education, and community partnerships in enhancing care for underserved Huntington’s disease populations.
Objectives/Goals: To observe mechanisms of natural supplements and their links and similar pathways to chemotherapy and hormone therapy in order to use natural therapies as a way to ease treatment side effects in breast cancer patients. Methods/Study Population: A systematic search was conducted using databases such as PubMed and Google Scholar, using search terms “breast cancer,” “treatment,” “pathways,” “targets,” and “cell lines” in combination with “natural therapies” as well as “hormone therapies” and “chemotherapies” to understand drug and supplement mechanisms. ClinicalTrials.gov was used to investigate studies using natural therapies used to treat side effects of cancer treatments. Promising results were discovered on the effectiveness of natural therapies and their correlation with treatment for breast cancer. Results/Anticipated Results: Preclinical evidence supports 23 natural remedies being used to ease side effects brought on by chemotherapy. These natural supplements are shown to affect at least one of the seven breast cancer cell lines observed. Fifty-two total clinical trials were used to verify the preclinical models of the 23 natural remedies, and the clinical trials would be patient symptom assessment-based, or determining tumor growth or shrinkage. Many of these clinical trials, however, did not supply results. This shows that there is a gap in getting participants for oncology-related clinical studies. With the trials that supplied results, 16 natural remedies have clinical data showing their ability to be used to ease common chemotherapy side effects, or even further leading to cancer death in related cell lines. Discussion/Significance of Impact: There are not many specific findings about young women and post-menopausal women being affected by breast cancer (despite being more sensitive groups). Looking into differences in biology, reactions to treatment and effectiveness of treatment, and clinical trials with supplements between these groups could address issues affecting them.
Research management, operations, and administration
Objectives/Goals: CTSA programs’ requests for applications (RFAs) can be hindered by misalignments with grantees’ needs and expectations. Using a customer discovery approach, we identified real and perceived barriers to conducting pragmatic EHR-embedded trials (PEET) to inform RFA optimization, demonstrating how this funding opportunity addressed barriers. Methods/Study Population: Using Colorado Profiles, a research networking tool, we identified investigators who engaged in PEET-type research across the Colorado Clinical and Translational Sciences Institute (CCTSI) partnering institutions. We invited 33 investigators representing key centers and departments to participate in 30-minute, virtual customer discovery interviews about their experiences conducting PEET-type research within CCTSI’s PEET health system partner, UCHealth. Interviews were conducted using a semi-structured interview guide and were synthesized using a Value Proposition Canvas to identify relevant investigator “jobs-to-be-done,” pain points and potential benefits and strategies to optimize our internal RFA (now in its third year) to address these. Results/Anticipated Results: Twenty-one investigators participated in interviews, including five previous applicants. Two key “customer segments” emerged from interviews: 1) early-career investigators, who wanted to build connections and competencies related to PEET-type research and were often transitioning to independent funding; and 2) experienced investigators, who were focused on larger grants, but valued support in interfacing with UCHealth around both research implementation and informatics. For both groups, while the research funding was seen as beneficial, the true value of the PEET support was the facilitation of a relationship with the health system. Potential changes to the PEET RFA include eligibility clarifications, increased emphasis on health system liaison support, and increased budget flexibility. Discussion/Significance of Impact: In PEETs, alignment of the health system, research infrastructure, and investigators is essential to trial success. Through this process, we identified key unmet needs for investigators and opportunities to optimize this internal RFA to enhance overall alignment between institutional capacities and investigator needs.
Objectives/Goals: The Michigan Institute for Clinical & Health Research (MICHR) needs to maintain a balanced portfolio of initiatives with respect to the extent of innovation sought and the stage of implementation. We created a Translational Science (TS) Dashboard to visualize this balance of intent and execution. Methods/Study Population: In designing the dashboard, we considered innovation along a spectrum: making incremental changes to our current offerings; seeking out new offerings or audiences; and seeking both new offerings and new audiences. We also used MICHR’s TS Framework that guides both the identification of roadblocks along the translational spectrum and the development of potential solutions to those roadblocks. Categories in the TS Framework help us understand if innovation efforts are in the early stages of problem framing or later stages of testing, iterating, and/or disseminating. Using co-creation methods, we partnered with various MICHR program teams, whose initiatives represent a mix of innovation categories as well as framework implementation phases, to optimize the design and understand the utility of the dashboard. Results/Anticipated Results: We worked with various programmatic teams at MICHR to help them understand the elements of the dashboard and to co-create the dashboard interface. Our methods also helped teams understand the “right” amount of innovation for their programs, ensuring they considered both differentiation and resource constraints as well as alignment with MICHR’s overarching strategic goals. Programs had different resource considerations, tolerance for risk, and unmet customer needs that informed how to right-size their innovation portfolio and where efforts should map along the stages of roadblock identification and solution crafting. The perspectives and insights of MICHR’s executive leadership were key to informing how the dashboard could support data-informed decisions at the institute level. Discussion/Significance of Impact: The TS Dashboard can help both MICHR program and institute leaders understand how projects map along different phases of discovery, implementation, and innovation, ensuring that the portfolio of activities is appropriately balanced.
Objectives/Goals: The Michigan Institute for Clinical & Health Research (MICHR) created an eight-phase adaptive Translational Science Framework to guide us in selecting and solving translational science problems. We operationalized the initial problem selection phases and assessed utility of various methods in shaping complex problems for solution design. Methods/Study Population: We identified three high-priority strategic domains where there was potential to improve the efficiency and effectiveness of research and related processes. Starting with broad problem statements, we engaged a wide array of stakeholders and end-users in a sequence of methods to reduce ambiguity, uncover root causes, and clarify actionable challenges. The methods we selected align with the four problem selection/problem analysis phases of our Translational Science Framework: contextualize, frame, map, and craft. Methods used included landscape and workforce assessments; purpose and scoping sessions; design research strategies; systems mapping; quantitative needs assessments; and translational science proposal pitches. Results/Anticipated Results: Across the three strategic domains, we successfully reframed and scaled ill-defined problem statements into translational science questions that are actionable, meaningful, feasible, and relevant. The outputs of each problem selection/problem analysis phase served as critical inputs for subsequent phases; for example, synthesis of landscape and workforce assessments in the contextualize phase provided critical substrate for structuring the design research and broad scale needs assessments in the frame phase. This funneling approach brought continuous focus and clarity to the problem statements. A variety of metrics embedded within the phases informed performance, progress, and decision-making, which enabled rapid adjustments in the face of evolving contexts and unforeseen challenges. Discussion/Significance of Impact: In the absence of translational science problem analysis, we risk not addressing actual needs, duplicating effort, and/or creating unwanted solutions. The methods and metrics within the analysis phases of our Translational Science Framework promote iterative refinement of intractable problems, with the goal of yielding impactful solutions.